Urological cancer, Malmö
121 – 130 of 544
                - show: 10
- |
- sort: year (new to old)
        Close
        
            
    
        Embed this list
<iframe src=""
              width=""
              height=""
              allowtransparency="true"
              frameborder="0">
            </iframe>
        - 2022
- 
                        Mark
        EAU-EANM Consensus Statements on the Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Patients with Prostate Cancer and with Respect to [177Lu]Lu-PSMA Radioligand Therapy
    
    - Contribution to journal › Article
 
- 
                        Mark
        Recurrence pattern in localized RCC : results from a European multicenter database (RECUR)
    
    - Contribution to journal › Article
 
- 
                        Mark
        The STAT3 inhibitor GPB730 enhances the sensitivity to enzalutamide in prostate cancer cells
    
    - Contribution to journal › Article
 
- 
                        Mark
        Assessing the accuracy of [18F]PSMA-1007 PET/CT for primary staging of lymph node metastases in intermediate- and high-risk prostate cancer patients
    
    - Contribution to journal › Article
 
- 
                        Mark
        Robot-assisted nephroureterectomy for upper tract urothelial carcinoma—feasibility and complications : a single center experience
    
    - Contribution to journal › Article
 
- 
                        Mark
        EANM-EAU consensus on PSMA PET/CT in respect to radioligand therapy ([177Lu]Lu-PSMA)
    
    - Contribution to journal › Debate/Note/Editorial
 
- 
                        Mark
        Experimental in vivo model to evaluate the impact of Cernitin™ on pain response on induced chronic bladder inflammation
    
    - Contribution to journal › Article
 
- 
                        Mark
        Plasma and Urine Free Glycosaminoglycans as Monitoring Biomarkers in Nonmetastatic Renal Cell Carcinoma—A Prospective Cohort Study
    
    - Contribution to journal › Article
 
- 
                        Mark
        A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome : No Evidence of Benefit, Supported by Epidemiology and In Vitro Data
    
    - Contribution to journal › Article
 
- 
                        Mark
        Community-onset urosepsis : incidence and risk factors for 30-day mortality–a retrospective cohort study
    
    - Contribution to journal › Article
 
